On October 30, 2025 Lantern reported it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas. The symposium, hosted by Dr. Serdar Bozdag and the newly established Center for Computational Life Sciences, brings together leading researchers advancing the intersection of artificial intelligence and biomedicine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Lantern Pharma team will deliver two presentations demonstrating how machine learning is transforming drug development and precision oncology through specific AI modules that are already delivering value to Lantern’s drug development efforts and other pharmaceutical companies and researchers:
"Machine Learning Ensemble Models for In Silico Screening and Prediction of Blood-Brain Barrier Permeability: A Comprehensive Approach Using Molecular Fingerprints and Descriptors". This presentation will showcase predictBBB.ai, Lantern’s commercially deployed platform that achieves 94.1% accuracy in predicting blood-brain barrier permeability—placing it at the top of the Therapeutic Data Commons leaderboard. The platform predicts BBB permeability in days rather than the months or years required by traditional methods, with the ability to screen 200,000 drug candidates in under a week. The ensemble model has been blindly validated on over 1,300 unseen molecules, demonstrating both accuracy and scalability for pharmaceutical companies developing CNS-targeted therapeutics and is available now as a commercial-ready resource.
"Machine Learning Models for Liquid Biopsy-Based Treatment Response Prediction and Biomarker Discovery in Cancer" Lantern will demonstrate LBx-AI, a production-ready platform that transforms liquid biopsy data into actionable insights with 86% accuracy in predicting treatment response for non-small cell lung cancer patients. Using a novel pathway-level engineering approach, the platform identifies complex biomarkers and pathway analytics that would be missed by traditional single-mutation analysis—with 20 out of 21 significant predictive markers being engineered pathway features. Beyond treatment prediction, LBx-AI can infer solid tumor characteristics from circulating tumor DNA, including accurate prediction of PD-L1 expression levels (0.76 Pearson correlation). Lantern is actively collaborating with world-class research institutions to further validate and improve the models’ performance across a number of tumor types, including GBM, and breast cancer.
Lantern believes that the platforms stand apart through three key differentiators: proven commercial deployment, dramatically compressed drug development timelines, and the generation of novel insights previously inaccessible through conventional methods. While traditional BBB permeability testing and biomarker discovery require months to years of laboratory work, Lantern’s AI models deliver comprehensive insights for drug development, candidate optimization, and target identification within days—maintaining enterprise-level scalability throughout. This transformation from lengthy experimental cycles to rapid computational analysis represents a fundamental shift in how pharmaceutical companies can approach drug discovery and development.
These advanced AI models power Lantern’s comprehensive cancer drug development ecosystem, which was initially developed as RADR. LBx-AI serves as a core component of RADR, Lantern’s AI-driven platform that accelerates precision oncology drug development, while predictBBB.ai operates as a standalone service helping pharmaceutical companies and research teams reduce development costs and improve success rates for CNS-targeted therapeutics.
"Our team is excited to share our efforts and platforms with leading researchers at this inaugural AI symposium," said Panna Sharma, President and CEO at Lantern Pharma. "We’re honored to present alongside distinguished researchers and look forward to engaging with the scientific community. Our vision extends beyond these current capabilities—we’re committed to making these powerful AI tools available as open-access platforms, democratizing advanced computational methods for researchers worldwide."
The symposium will feature keynote speaker Dr. Iman Hajirasouliha, Associate Professor of Systems and Computational Biomedicine at Weill Cornell Medicine, member of the Englander Institute for Precision Medicine and the Meyer Cancer Center, and Co-Director of the Tri-I Computational Biology and Medicine Ph.D. program.
For more information about the AI4BM symposium, visit: View Source
(Press release, Lantern Pharma, OCT 30, 2025, View Source;Research-Platforms-at-Inaugural-AI-for-Biology-and-Medicine-Symposium-at-UNT/default.aspx [SID1234657170])